Cargando…

A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer

BACKGROUND: Pembrolizumab and sintilimab have both been approved by the China National Medical Products Administration (NMPA) for the first-line treatment of advanced non-small cell lung cancer (NSCLC). These two drugs have several differences in biological characteristics and population in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kai, Fu, Yifan, Zeng, Daxiong, Chen, Tao, Wang, Changguo, Jiang, Junhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987820/
https://www.ncbi.nlm.nih.gov/pubmed/35399230
http://dx.doi.org/10.21037/jtd-22-225
_version_ 1784682827221041152
author Wu, Kai
Fu, Yifan
Zeng, Daxiong
Chen, Tao
Wang, Changguo
Jiang, Junhong
author_facet Wu, Kai
Fu, Yifan
Zeng, Daxiong
Chen, Tao
Wang, Changguo
Jiang, Junhong
author_sort Wu, Kai
collection PubMed
description BACKGROUND: Pembrolizumab and sintilimab have both been approved by the China National Medical Products Administration (NMPA) for the first-line treatment of advanced non-small cell lung cancer (NSCLC). These two drugs have several differences in biological characteristics and population in clinical trials. The current retrospective study was conducted to compare the efficacy and safety of sintilimab and pembrolizumab as first-line treatments in patients with advanced NSCLC. METHODS: Consecutive patients with advanced NSCLC who received sintilimab or pembrolizumab as first-line therapy, with or without chemotherapy, from November 2018 to October 2021 in the First Affiliated Hospital of Soochow University and Dushu Lake Hospital Affiliated to Soochow University were retrospectively reviewed. Clinical data and treatment response were collected and survival was followed up. Kaplan-Meier method was used to estimate survival curves. The patients were divided into the sintilimab group and the pembrolizumab group according to the PD-1 inhibitors they received during treatment. The primary objective was to compare objective response rate (ORR) and progression-free survival (PFS) between the two groups. The secondary objectives were to compare disease control rate (DCR) and analyze adverse events (AEs) of the two groups. RESULTS: A total of 124 patients were enrolled, including 68 patients (54.8%) in the sintilimab group and 56 patients (45.2%) in the pembrolizumab group. The baseline characteristics of the patients were comparable between the two groups. The ORR was 50% in the sintilimab group and 46.4% in the pembrolizumab group (P=0.69). The DCR was 89.7% and 89.3% in the sintilimab group and the pembrolizumab group, respectively (P=0.94). The median PFS time was 9.9 months in patients treated with sintilimab compared to 10.8 months in patients on pembrolizumab treatment [hazard ratio (HR) =0.960; 95% confidence interval (CI): 0.574–1.606; P=0.875]. The median OS time was not reached in either group of patients. The incidence of grade 3–4 treatment-related adverse events (TRAEs) was 25% (17/68) in the sintilimab group and 21.4% (12/56) in the pembrolizumab group. CONCLUSIONS: Sintilimab has similar efficacy to pembrolizumab as a first-line treatment option for patients with advanced NSCLC in clinical practice, with manageable AEs.
format Online
Article
Text
id pubmed-8987820
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-89878202022-04-08 A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer Wu, Kai Fu, Yifan Zeng, Daxiong Chen, Tao Wang, Changguo Jiang, Junhong J Thorac Dis Original Article BACKGROUND: Pembrolizumab and sintilimab have both been approved by the China National Medical Products Administration (NMPA) for the first-line treatment of advanced non-small cell lung cancer (NSCLC). These two drugs have several differences in biological characteristics and population in clinical trials. The current retrospective study was conducted to compare the efficacy and safety of sintilimab and pembrolizumab as first-line treatments in patients with advanced NSCLC. METHODS: Consecutive patients with advanced NSCLC who received sintilimab or pembrolizumab as first-line therapy, with or without chemotherapy, from November 2018 to October 2021 in the First Affiliated Hospital of Soochow University and Dushu Lake Hospital Affiliated to Soochow University were retrospectively reviewed. Clinical data and treatment response were collected and survival was followed up. Kaplan-Meier method was used to estimate survival curves. The patients were divided into the sintilimab group and the pembrolizumab group according to the PD-1 inhibitors they received during treatment. The primary objective was to compare objective response rate (ORR) and progression-free survival (PFS) between the two groups. The secondary objectives were to compare disease control rate (DCR) and analyze adverse events (AEs) of the two groups. RESULTS: A total of 124 patients were enrolled, including 68 patients (54.8%) in the sintilimab group and 56 patients (45.2%) in the pembrolizumab group. The baseline characteristics of the patients were comparable between the two groups. The ORR was 50% in the sintilimab group and 46.4% in the pembrolizumab group (P=0.69). The DCR was 89.7% and 89.3% in the sintilimab group and the pembrolizumab group, respectively (P=0.94). The median PFS time was 9.9 months in patients treated with sintilimab compared to 10.8 months in patients on pembrolizumab treatment [hazard ratio (HR) =0.960; 95% confidence interval (CI): 0.574–1.606; P=0.875]. The median OS time was not reached in either group of patients. The incidence of grade 3–4 treatment-related adverse events (TRAEs) was 25% (17/68) in the sintilimab group and 21.4% (12/56) in the pembrolizumab group. CONCLUSIONS: Sintilimab has similar efficacy to pembrolizumab as a first-line treatment option for patients with advanced NSCLC in clinical practice, with manageable AEs. AME Publishing Company 2022-03 /pmc/articles/PMC8987820/ /pubmed/35399230 http://dx.doi.org/10.21037/jtd-22-225 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wu, Kai
Fu, Yifan
Zeng, Daxiong
Chen, Tao
Wang, Changguo
Jiang, Junhong
A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
title A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
title_full A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
title_fullStr A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
title_full_unstemmed A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
title_short A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
title_sort retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987820/
https://www.ncbi.nlm.nih.gov/pubmed/35399230
http://dx.doi.org/10.21037/jtd-22-225
work_keys_str_mv AT wukai aretrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT fuyifan aretrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT zengdaxiong aretrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT chentao aretrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT wangchangguo aretrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT jiangjunhong aretrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT wukai retrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT fuyifan retrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT zengdaxiong retrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT chentao retrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT wangchangguo retrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer
AT jiangjunhong retrospectivecohortstudyofsintilimabandpembrolizumabasfirstlinetreatmentsforadvancednonsmallcelllungcancer